Figure 5From: Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer Ki67 Biomarker in patients with an ER-α/ER-β score ratio between 1 and 1.5. Back to article page